To drugs left support

Many global pharmaceutical companies, having refused direct advertizing of the preparations to Russian Federation after the beginning of military operations in Ukraine, do not reduce expenditure for advance through the medical organizations, allocating it funds for researches and branch actions. In 2023 these expenses can grow by 5%, to 20,5 billion rubles. Dynamics can speak about aspiration of global players to keep a share in the Russian market though more modest indexation of payments, than earlier, facilitates to the local companies advance of the drugs. Photo: Deryugin Vasilii, newspaper "Kommersant" Payments international pharmaceutical companies...